Cargando…
Co-administration of tecovirimat and ACAM2000™ in non-human primates: Effect of tecovirimat treatment on ACAM2000 immunogenicity and efficacy versus lethal monkeypox virus challenge()()
Naturally occurring smallpox has been eradicated but research stocks of variola virus (VARV), the causative agent of smallpox, still exist in secure laboratories. Clandestine stores of the virus or resurrection of VARV via synthetic biology are possible and have led to concerns that VARV could be us...
Autores principales: | Russo, Andrew T., Berhanu, Aklile, Bigger, Catherine B., Prigge, Jon, Silvera, Peter M., Grosenbach, Douglas W., Hruby, Dennis |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors. Published by Elsevier Ltd.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6954297/ https://www.ncbi.nlm.nih.gov/pubmed/31677948 http://dx.doi.org/10.1016/j.vaccine.2019.10.049 |
Ejemplares similares
-
Tecovirimat for monkeypox
por: Halani, Sheliza, et al.
Publicado: (2022) -
Monkeypox in Patient Immunized with ACAM2000 Smallpox Vaccine During 2022 Outbreak
por: Turner, Matthew, et al.
Publicado: (2022) -
Effects of Treatment Delay on Efficacy of Tecovirimat Following Lethal Aerosol Monkeypox Virus Challenge in Cynomolgus Macaques
por: Russo, Andrew T, et al.
Publicado: (2018) -
Monkeypox treatment: Is tecovirimat the answer?
por: Niaz, Faizan, et al.
Publicado: (2022) -
Comparison of Biological, Pharmacological Characteristics, Indications, Contraindications and Adverse Effects of JYNNEOS and ACAM2000 Monkeypox Vaccines
por: Meo, Sultan Ayoub, et al.
Publicado: (2022)